MDMA's new executive director Stephen Northrup focusing on reimbursement issues, FDAMA implementation.
This article was originally published in The Gray Sheet
MDMA's NEW EXECUTIVE DIRECTOR STEPHEN NORTHRUP will be tasked with addressing coverage and reimbursement issues over the coming months, the Medical Device Manufacturers Association states in a Jan. 27 announcement. Effective Feb. 2, Northrup replaces outgoing Executive Director Jeffrey Kimbell, who is leaving to start his own Washington, D.C.-based lobbying firm, Jeffrey J. Kimbell & Associates.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.